Document:

EX-4.2

 Exhibit 4.2 

FIRST SUPPLEMENTAL INDENTURE 

FIRST SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”), dated as of April 1, 2015, between Salix Pharmaceuticals,
Ltd., a Delaware corporation, as issuer (the “Company”) and U.S. Bank National Association, as trustee (in such capacity, the “Trustee”). 

W I T N E S S E T H 
 WHEREAS,
the Company has heretofore executed and delivered to the Trustee an indenture, dated as of March 16, 2012 (the “Indenture”), providing for the issuance of 1.5% Convertible Senior Notes due 2019 (the “Notes”);

 WHEREAS, the Company entered into the Agreement and Plan of Merger, dated as of February 20, 2015 (as amended, restated or otherwise
modified from time to time, including, without limitation, by that certain Amendment No. 1 to Agreement and Plan of Merger, dated as of March 16, 2015, the “Merger Agreement”), by and among the Company, Valeant
Pharmaceuticals International, a Delaware corporation (“Valeant”), Valeant Pharmaceuticals International, Inc., a British Columbia corporation, and Sun Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of
Valeant (“Merger Sub”), pursuant to which, among other things, concurrently with the execution of this Supplemental Indenture, Merger Sub is being merged with and into the Company, with the Company being the surviving corporation in
such merger (the “Merger”); 
 WHEREAS, pursuant to the Merger Agreement and subject to the terms and conditions therein,
at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (the “Shares”) issued and outstanding immediately prior to the effective time of the Merger (other than certain Shares as
set forth in the Merger Agreement) is being converted into the right to receive $173.00, payable net to the holder in cash, without interest (the “Reference Property”), subject to any withholding of taxes required by applicable law;

 WHEREAS, the Merger constitutes a Merger Event under Section 15.06 of the Indenture; 

WHEREAS, pursuant to Section 11.01 of the Indenture, without the consent of the holders of any of the Notes at the time outstanding, the
Company and the Trustee are authorized to enter into one or more supplemental indentures thereto including pursuant to, inter alia, Section 11.01(g) thereof to make any change that does not materially adversely affect the rights of any
holder; 
 WHEREAS, pursuant to Section 15.06 of the Indenture, upon the occurrence of a Merger Event, the Company or the successor or
purchasing Person, as the case may be, shall execute with the Trustee a supplemental indenture providing for the conversion and settlement of the Notes as set forth in the Indenture; 

WHEREAS, pursuant to Sections 11.05, 12.03, 15.06(a) and 17.05(a)(i) of the Indenture, the Trustee has received an Officers’ Certificate
as conclusive evidence that this Supplemental Indenture complies with the requirements of the Indenture and is permitted or authorized by the Indenture and stating, inter alia, that, in the opinion of the signers thereof, all conditions
precedent, if any, provided for in the Indenture relating to this Supplemental Indenture have been complied with and that the Merger and this Supplemental Indenture comply with the provisions of Article 12 of the Indenture; and 

 WHEREAS, pursuant to Sections 11.05, 12.03 and 17.05(a)(ii) of the Indenture, the Trustee has
received an Opinion of Counsel as conclusive evidence that this Supplemental Indenture complies with the requirements of the Indenture and is permitted or authorized by the Indenture and stating, inter alia, that, in the opinion of such
counsel, all conditions precedent, if any, provided for in the Indenture relating to the Supplemental Indenture have been complied with and that the Merger and this Supplemental Indenture comply with the provisions of Article 12 of the Indenture;

 NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt of which is hereby
acknowledged, the Company and the Trustee hereby agree as follows: 
 1. Capitalized Terms. Capitalized terms used herein without
definition shall have the meanings assigned to them in the Indenture. 
 2. Agreement of Parties. 

(a) In accordance with Section 15.06 of the Indenture, from and after the effective time of the Merger, the right of the holders of Notes
to convert each $1,000 principal amount of Notes into cash, Shares or a combination of cash and Shares in accordance with the terms of the Indenture shall be changed to a right of such holders to convert each $1,000 principal amount of Notes into
the Reference Property, at the Conversion Rate applicable to the conversion of such Notes, in accordance with the terms and conditions of the Indenture. The provisions of the Indenture, as modified herein, shall continue to apply, mutatis
mutandis, to the holders’ right to convert each $1,000 principal amount of Notes into the Reference Property. Aggregate amounts of cash due to each holder upon such holder’s conversion of Notes shall be rounded up to the nearest cent.

 (b) The Company hereby confirms its obligations under the Indenture, including but not limited to the due and punctual payment of the
principal of (including any Fundamental Change Repurchase Price), accrued and unpaid interest and accrued and unpaid Additional Interest, if any, on all of the Notes, the due and punctual delivery or payment, as the case may be, of any consideration
due upon conversion of the Notes and the due and punctual performance of all of the covenants and conditions of the Indenture to be performed by the Company. 

3. Indenture Remains in Full Force and Effect. Except as supplemented hereby, all provisions of the Indenture shall remain in full
force and effect. 
 4. GOVERNING LAW. THIS SUPPLEMENTAL INDENTURE SHALL BE DEEMED TO BE A CONTRACT MADE UNDER THE LAWS OF NEW YORK,
AND FOR ALL PURPOSES SHALL BE CONSTRUED IN ACCORDANCE WITH THE LAWS OF NEW YORK (WITHOUT REGARD TO THE CONFLICTS OF LAWS PROVISIONS THEREOF). 

5. Multiple Counterparts. The parties may sign multiple counterparts of this Supplemental Indenture. Each signed counterpart shall be
deemed an original, but all of them together represent the same agreement. 
 6. Effect of Headings. The Section headings herein are
for convenience of reference only, are not to be considered a part hereof, and shall in no way modify or restrict any of the terms or provisions hereof. 

[Signature Pages Follow] 

  
 -2- 

 IN WITNESS WHEREOF, the parties hereto have caused this Supplemental Indenture to be duly
executed, all as of the date first above written. 
  

			
	SALIX PHARMACEUTICALS, LTD.
		
	By:		 /s/ William C. Bertrand, Jr.

	Name:		William C. Bertrand, Jr.
	Title:		Acting Chief Operating Officer, Executive
			Vice President and General Counsel

  
 [Signature Page to
First Supplemental Indenture Relating to 1.5% Convertible Senior Notes due 2019] 

 
			
	U.S. BANK NATIONAL ASSOCIATION, as Trustee
		
	By:		 /s/ Paul Vaden

	Name:		Paul Vaden
	Title:		Vice President

  
 [Signature Page to
First Supplemental Indenture Relating to 1.5% Convertible Senior Notes due 2019]EX-10.1

 Exhibit 10.1 
  

 
 April 1, 2015 

The Coca-Cola Company, through its 

       Coca-Cola North America Division 

PO Box 1734 
 Atlanta, GA 30301 

Attn: Mr. Louis Martin, Senior Vice President System Evolution 

Dear Louis: 
 We refer you to the Agreement entered
into on December 17, 2014 (the “Agreement”) between Coca-Cola Bottling Co. Consolidated (“Bottler”) and The Coca-Cola Company through its Coca-Cola North America Division (“TCCC”) regarding certain payments to be
made by Bottler to TCCC for consent to Bottler’s distribution of Products of Monster Energy Corporation (“MEC”). Capitalized terms not defined herein shall have the definitions ascribed in the Agreement. Notwithstanding any term in
the Agreement to the contrary, TCCC and Bottler agree that Bottler shall not be obligated to make the upfront payment described in paragraph A. of the section of the Agreement titled “Bottler Payment to Company for Distribution Rights”
until the later of (i) the Commencement Date or (ii) June 30, 2015 to allow for reconciliation of the number of SPCs sold in the Additional Territory for the twelve (12) months preceding the Commencement Date to enable
determination of the upfront payment. 
 Except as modified by the terms of this letter, all terms and conditions in the Agreement remain in full
force and effect. Please acknowledge TCCC’s agreement with the terms of this letter by signing below in the space provided. 
 Sincerely, 

 

	
	 /s/ Umesh Kasbekar

	 Umesh Kasbekar, SVP, Planning & Administration

	 Coca-Cola Bottling Co. Consolidated

	
	 Agreed and Acknowledged:

	
	 /s/ Louis Martin

	 Louis Martin, Senior Vice President System Evolution

	 The Coca-Cola Company, by and through

	 Its Coca-Cola North America Division

 4100 Coca-Cola Plaza, Charlotte, North Carolina 28211-3481         
(704) 557-4400          P.O. Box 31487, Charlotte, North Carolina 28231-1487 

www.cokeconsolidated.comPODD EX10.1_2015-04-01 8K

Exhibit 10.1

March 30, 2015

Allison Dorval
94 Bigelow Street, Apt 3
Brighton, MA 02135
    
Dear Allison: 

The purpose of this letter agreement (the “Agreement”) is to set forth the terms of your separation from Insulet Corporation (“Insulet” or the “Company”). The Transition Benefits described below are contingent on your agreement to and compliance with the terms of this Agreement, including your signing and not revoking of this Agreement.  This Agreement will become effective and enforceable on the eighth day after you sign it, provided it is not revoked before that time (the “Effective Date”).

1.    Transition Role.   Effective May 4, 2015, you will no longer hold the position of Chief Financial Officer and any of the Company’s subsidiaries or entities affiliated with the Company.  Absent earlier termination, your employment shall end on July 3, 2015.  The last date of your employment shall be deemed to be the “Separation Date”.  Also effective May 4, 2015 and continuing until July 3, 2015 (the “Transitional Employment Period”), you shall remain employed by the Company in a “Transition Role”.  You shall at all times, including during the Transitional Employment Period, act in a professional manner in any communications with the Company.  Both before and during the Transition Employment Period, you shall act in a positive and constructive manner, perform any assigned tasks, and otherwise assist Insulet in the transition of work in connection with any of the duties you have performed at Insulet, or otherwise perform any specific project assigned to you by Insulet.  Your employment status as an at-will employee shall remain at all times, including during the Transition Employment Period.  
 
During the Transitional Employment Period, you shall receive the following Transition Pay and Benefits:  (i) continuation of your base bi-weekly salary, subject to all ordinary payroll taxes and withholdings, in accordance with Insulet’s payroll policies and procedures; and (ii) continuation of your participation in Insulet’s employee benefits programs and employee insurance benefits programs, but only to the extent that you currently participate in such programs and remain eligible under any applicable plan document(s), and you shall continue to vest in any outstanding stock options or restricted stock units previously granted to you by the Company will continue on account of your employment during through the Separation Date.   
    
You specifically acknowledge that offer and continuation of your employment during the Transitional Employment Period is being provided as part of the separation of your employment and is in consideration of your agreements, including the release of claims set forth in Section 8 included in this Agreement, and that nothing herein alters your status as an employee at will during the Transition Employment Period.  Notwithstanding the foregoing, the Company only will terminate your employment prior to the Separation Date if you materially breach your obligations to the Company.

On the Separation Date, the Company shall pay your final accrued but unpaid base salary and any accrued but unused vacation earned through the Separation Date.  You also shall be entitled to be reimbursed for reasonable business expenses incurred prior to the Separation Date in connection with your employment subject to the Company’s policies and procedures with respect to expense reimbursement.

2.     Termination Benefits.  Provided you enter into, do not revoke, and comply with this Agreement, and in exchange for the mutual covenants set forth in this Agreement, and provided further that you sign the affirmation of this Agreement and the Release of Claims set forth in Section 8 below in the form attached hereto as Exhibit A, the Company will provide the following Termination Benefits:

(i)    Continuation of your base bi-weekly salary of Eleven Thousand Five Hundred Thirty Eight Dollars and Forty Six Cents ($11,538.46) for twelve (12) months (for a total gross payment of $300,000.00), less applicable tax deductions and withholdings, and any other authorized deductions (“Severance Pay”).  Such amounts shall be paid in substantially equal installments in accordance with the Company’s regular payroll practice beginning on the first payroll date that occurs after the Separation Date.  As used herein, Severance Period means the period from July 4, 2015 to July 3, 2016.

1Except for the obligations set forth in Sections 2 and 3 of this Agreement which shall solely be the obligations of Insulet Corporation, whenever the terms “Insulet” or “the Company” are otherwise used in this Agreement, they shall be deemed to include Insulet Corporation and any related entities (including, without limitation, any divisions, affiliates, parents or subsidiaries of Insulet Corporation), and its and their respective current and former officers, directors, employees, agents, successors and assigns.

(ii)     Upon your making a timely COBRA election, and provided that you timely pay your regular employee contribution toward your medical and dental insurance premiums as required by the Company or its COBRA administrator, the Company will pay the standard employer portion of your medical and dental insurance premiums until the earlier of (a) the last day of the Severance Period, (b) the date you become eligible for health insurance through another employer, or (c) the date you otherwise become ineligible for COBRA.  The Company’s obligations under this subsection are contingent on you making a timely COBRA election.  Additionally, the Company shall only be required to continue and contribute to your medical and dental insurance under this subsection to the same extent that such insurance is provided to persons employed by the Company.  After the expiration of the Severance Period, you will have the right to continue your medical and dental insurance solely at your own cost pursuant to the provisions of the Consolidated Omnibus Budget Reconciliation Act of 1985 (COBRA) to the extent you and your qualified beneficiaries remain eligible.  The “qualifying event” under COBRA shall be the Separation Date. 

(iii)     The Company shall pay you Bonus Payments of (a) One Hundred Fifty Thousand Dollars ($150,000.00), which amount is equal to your 2015 annual bonus target, and (b) Seventy Five Thousand Dollars ($75,000.00), which amount reflects a pro-rata 2015 bonus.  Such Bonus Payments shall be made in 24 equal installments over the 12-month Severance Period commencing with the first payroll period following the Separation Date, and shall be subject to deductions for state and federal income and welfare taxes and any other mandatory deductions under applicable laws. 
 
(iv)  Reimbursement of up to a maximum of Fifteen Thousand Dollars ($15,000) for documented expenses incurred for professional outplacement services.
 
3.    2014 Bonus.  You acknowledge that you have been paid a 2014 bonus in the gross amount of Seventy-Nine Thousand Six Hundred Dollars ($79,600.00), less state and federal employment related taxes, and such amount represents the full amount of bonus due to you.            

4.    Stock Options.  You will be entitled to exercise only those stock options granted under the Insulet Corporation 2007 Stock Option Incentive Plan (“Equity Plan”), and any amendments thereto, that are vested through the Separation Date, and only in accordance with the terms and conditions of the applicable plan(s), and any amendments thereto, including (without limitation) those provisions regarding the time in which you have to exercise vested options.  Except for those vested options, you acknowledge and agree that you do not now have, and will not in the future have, rights to vest in any other equity plans (of whatever name or kind, including, without limitation, any stock option plan) that you  participated in or were eligible to participate in during your employment with Insulet.

		
	5.
	Other Acknowledgements.  You acknowledge and agree:

(i)     That your entitlement to the Termination Benefits is subject to and conditioned upon your execution, non-revocation and compliance with this Agreement.  

(ii)      That the Termination Benefits are equal to the Termination Benefits set forth in this Agreement equal or exceed those termination benefits set forth in the Insulet Corporation Amended and Restated Executive Severance Plan (“the ESP”) (attached hereto as Exhibit B), and that this Separation Agreement and the covenants set forth herein (including the release of claims set forth in Section 7) are a condition precedent to your receiving the Termination Benefits.  

(iii)      That except for your covenants set forth in Section 5 of the ESP, and the provisions set forth in Sections 4, 7, 8 and 9 of the ESP, all of which are incorporated by reference, this Agreement supersedes the ESP, and any other rights and obligations contained in the ESP are hereby extinguished, and you specifically acknowledge that you have no further entitlement to any severance pay or any other economic benefits under the ESP.  

(iv)      Subject to Section 11(vii), the Termination Benefits shall confer no benefit on anyone other than the parties hereto. 

(v)   That except for (a) the specific financial consideration set forth in this Agreement, (b) earned but unpaid regular wages earned through the Separation Date, and (c) accrued but unused vacation (which shall be paid to 

you in accordance with applicable law), you are not now and shall not in the future be entitled to any other compensation or benefit including, without limitation, other wages, commissions, bonuses, incentives, vacation pay, holiday pay, stock options or other equity, or any other form of compensation or benefit. 

6.    Confidentiality and Other Obligations.  You expressly acknowledge and agree to the following:
(i)      That the provisions of Section 5 of the ESP are hereby incorporated herein by reference.

(ii)      That you will promptly return to the Company all the Company documents, electronic, hardcopy otherwise (and any copies) and other Company property, on or before the Separation or promptly upon an earlier request by the Company.  

(iii)  That you will abide by the terms of the Employee Nondisclosure and Developments Agreement and the Non-Competition and Non-Solicitation Agreement attached hereto as Exhibit C, the terms of which are hereby incorporated into this Agreement by reference, and that you otherwise will keep all confidential information and trade secrets of the Company confidential; however, to the extent that the provisions of Section 5 of the ESP impose obligations on you in excess of those set forth in Exhibit C, the provisions of the ESP shall prevail.  

(iv)  That you also will abide by any and all common law and/or statutory obligations relating to protection and non-disclosure of the Company’s trade secrets and/or confidential and proprietary documents and information.

(v)  That all information relating in any way to this Agreement, including the terms and amount of financial consideration provided for in this Agreement, shall be held confidential by you and shall not be publicized or disclosed to any person or entity (other than an immediate family member, legal counsel, or financial advisor, provided that any such individual to whom disclosure is made agrees to be bound by these confidentiality obligations), except as otherwise mandated by law.

(vi)  During your employment and after the termination of your employment you agree not to make or cause to be made, directly or indirectly, any statement to any person disparaging the Company or any of its stockholders, directors, officers or employees or commenting unfavorable or falsely on the character, business judgment, services, products, business practices or business reputation of the Company or any of its stockholder, directors, officers or employees.  

(vii) That you have disclosed in writing to the Company (and specifically its General Counsel) any conduct or planned conduct by the Company that you believe would violate any legal obligation, statutory or regulatory, and except for such disclosure, you are not aware of any conduct or planned conduct that would violate any legal obligation, statutory or regulatory.

(viii)  To the extent that any of your obligations under Sections 4 and 5 of the Executive Severance Plan exceed those set forth in Exhibit C, then the provisions of the Executive Severance Plan shall prevail. 

(ix)   If you breach any covenant in this Section 6 or your obligations set forth in Section 5 of the ESP, such breach shall relieve the Company of any further obligations under this Agreement and, in addition to any other legal or equitable remedy available to the Company, shall entitle the Company to end your employment if you are still employed, and/or to stop providing and/or recover any Termination Benefits payable or paid to you (or on your behalf) pursuant to Section 2 of this Agreement.  Notwithstanding the foregoing, prior to declaring you to be in breach, the Company will notify you of the nature of the breach and, if the Company reasonably determines that such breach can be promptly cured, will provide you with an opportunity (of not more than 7 days) to effect such a cure.   

7.    Cooperation.  During the Severance Period, you will make yourself available to Insulet, upon reasonable notice, either by telephone or, if Insulet believes necessary, in person to assist Insulet in any matter relating to the services performed by you during your employment with Insulet including, but not limited to, transitioning your duties to others at Insulet, and ensuring that all documentation is recorded fully and completely.  Also, during the Severance Period and thereafter, you further agree that you will cooperate fully with Insulet in the defense or prosecution of any government investigation and any government or third-party claim or action now in existence or which may be brought or threatened in the future against or on behalf of Insulet, in

cluding any claim or action against its directors, officers and employees.  Your cooperation in connection with any such claim or action shall include your being available, within reason given the constraints of personal commitments, future employment or job search activities, to meet with Insulet and its legal counsel to prepare for any proceeding, to provide truthful affidavits, to assist with any audit, inspection, proceeding or other inquiry, and to act as a witness in connection with any litigation or other legal proceeding affecting Insulet.  Insulet shall reimburse you for documented and reasonable expenses incurred in providing such cooperation.  You further agree that should an individual representing a party adverse to the business interests of Insulet (including, without limitation, anyone threatening any form of legal action against Insulet) contact you (directly or indirectly), you will promptly (within 48 business hours) inform (in writing) the General Counsel of Insulet of that fact, unless prohibited from doing so under court order.  

8.     Release of Claims.  You hereby acknowledge and agree that by signing this Agreement, you are waiving your right to assert any Claim (as defined below) against the Company arising from acts or omissions that occurred on or before the date you sign this Agreement.  Please note the definition of the Company contained in footnote 1 of this Agreement.

Your waiver and release is intended to bar any form of legal claim, lawsuit, charge, complaint or any other form of action (jointly referred to as “Claims”) against the Company seeking money or any other form of relief, including but not limited to equitable relief (whether declaratory, injunctive or otherwise), damages or any other form of monetary recovery (including but not limited to back pay, front pay, compensatory damages, emotional distress damages, punitive damages, attorneys’ fees and any other costs), each as they may have been amended through the Separation Date or Effective Date, whichever is later. You understand that there could be unknown or unanticipated Claims resulting from your employment with the Company and the termination of your employment, and you agree that such Claims are included in this waiver and release.  You specifically waive and release the Company from any Claims arising from or related to your employment relationship with the Company or the termination of your employment, including without limitation Claims under any statute, ordinance, regulation, executive order, common law, constitution and/or other source of law of any state, country and/or locality (collectively and individually referred to as “Law”), including but not limited to the United States, the Commonwealth of Massachusetts, and any other state or locality where you worked for the Company.  

Without limiting the foregoing general waiver and release, except for Claims resulting from the failure of Neighborhood to perform its obligations under this Agreement, you specifically waive and release Neighborhood from any Claims arising from or related to your employment relationship with Neighborhood or the termination thereof, including without limitation: 

 (i)    Claims under any Law concerning discrimination, harassment or fair employment practices, including but not limited to Massachusetts General Laws Chapter 151B, Title VII of the Civil Rights Act of 1964 (42 U.S.C. § 2000e et seq.), 42 U.S.C. § 1981, the Age Discrimination in Employment Act (29 U.S.C. § 621 et seq.) and the Americans with Disabilities Act (42 U.S.C. § 12101 et seq.), each as they may have been amended through the Separation Date or Effective Date, whichever is later; 

(ii)    Claims under any Law relating to wages, hours, whistleblowing, leaves of absences or any other terms and conditions of employment, including but not  limited to the Family and Medical Leave Act of 1993 (29 U.S.C. § 2601 et seq.), the Massachusetts Payment of Wages Law (Massachusetts General Laws Chapter 149, §§  148, 150), Massachusetts General Laws Chapter 149 in its entirety, and Massachusetts General Laws Chapter 151 in its entirety (including but not limited to the minimum wage and overtime provisions), each as they may have been amended through the Separation Date or Effective Date, whichever is later.   You specifically acknowledge that you are waiving any Claims for unpaid wages under these and other Laws;  

(iii)   Claims under any local, state or federal common law theory; 

(iv)   Claims arising under the Company’s policies or benefit plans; and

(v)   Claims arising under any other Law or constitution.

This Section 8 shall not release the Company from any obligation expressly set forth in this Agreement, or preclude you from pursuing any claims to enforce this Agreement.  In addition, nothing in this Agreement operates as a waiver of or otherwise impacts your (x) vested benefits under the Company’s 401(k) plan, (y) vested equity under the Company’s stock plan(s), and (z) any rights to indemnification, whether pursuant to insurance policy including directors and officers insurance, contract, the Company’s articles of incorporation, by-laws, and/or charter, or applicable law. You acknowledge and agree that, but for providing this waiver and release, you would not be receiving the Termination Benefits provided for in this Agreement.

Also, consistent with the provisions of state and federal discrimination laws (the “Discrimination Laws”), nothing in the general waiver and release set forth in Section 8 above shall be deemed to prohibit you from challenging the validity of this release under the Discrimination Laws or from filing a charge or complaint of age or other employment related discrimination with the Equal Employment Opportunity Commission (“EEOC”) or similar state agency, or from participating in any investigation or proceeding conducted by the EEOC or such state agency.  However, the release in Section 8 does prohibit you from seeking or receiving monetary damages or other individual-specific relief in connection with any such charge or complaint of age or other employment-related discrimination.  Further, nothing in this Agreement shall be deemed to limit the Company’s right to seek immediate dismissal of such charge or complaint on the basis that your signing of this Agreement constitutes a full release of any individual rights under the Discrimination Laws, or the Company’s right to seek restitution or other legal remedies to the extent permitted by law of the economic benefits provided to you under this Agreement in the event that you successfully challenge the validity of this release and prevail in any claim under the Discrimination Laws.

10.    Insulet Instruction.  The Company agrees to instruct its senior management team to not make any statements that are professionally or personally disparaging about, or adverse to, your interests, including, but not limited to, any statements that disparage you, and shall further instruct its senior management team to not engage in any conduct that could reasonably be expected to harm professionally or personally your reputation.  You understand and agree that the Company’s sole obligation hereunder is to provide such instructions, and it is not responsible nor shall it be liable in the event an employee of the Company violates such instruction.  In addition, prior to publication, Company will show you any press release, or external or internal announcement, and permit you to make comments to the same; however, the contents of any announcement shall be in the sole discretion of Insulet.  

11.    Miscellaneous Provisions.  

(i)    Except as otherwise expressly provided in this Agreement (and specifically, your obligations under Exhibits B and C), and your rights under the Equity Plan and any restricted stock and/or stock option agreements), this Agreement supersedes any and all other prior oral and/or written agreements, and sets forth the entire agreement between you and the Company.  No variations or modifications hereof shall be deemed valid unless reduced to writing and signed by the parties hereto.  

(ii)   This Agreement shall be deemed to have been made in the Commonwealth of Massachusetts, shall take effect as an instrument under seal, and shall be governed by the law of the Commonwealth of Massachusetts, without giving effect to conflict of law principles.   

(iii)    You agree that any action, demand, claim or counterclaim relating to the terms and provisions of this Agreement, or to its breach, shall be commenced in Massachusetts in a court of competent jurisdiction, and you further acknowledge that venue for such actions shall lie exclusively in Massachusetts and that material witnesses and documents would be located in Massachusetts.  You also agree that a court in Massachusetts will have personal jurisdiction over you, and you waive any right to raise a defense of lack of personal jurisdiction by such a court.

(iv)   Both parties agree that any action, demand, claim or counterclaim arising out of this Agreement shall be resolved by a judge alone, and both parties hereby waive and forever renounce the right to a trial before a civil jury.  

(v)    If your release of Claims pursuant to Section 8 is found to be unenforceable in whole or part (except for your release of federal age discrimination Claims, which shall not be subject to this sentence), the Company will have the option, in its sole discretion, to enforce the portions of the Agreement found not to be unenforceable.  In the event that any other provision of this Agreement is determined to be unenforceable in whole or part (including your release of federal age discrimination Claims), the remainder of the Agreement shall be enforced in full.

(vi)    The parties intend that all payments and benefits provided for in this Agreement will be administered in accordance with Section 409A of the Internal Revenue Code of 1986, as amended (“Section 409A”).  To the extent that any provision of this Agreement is ambiguous as to its compliance with Section 409A, the provision shall be read in such a manner so that all payments hereunder either comply with Section 409A or are exempt from Section 409A. It is intended that each installment of the payments and benefits provided under Section 2 of this Agreement shall be treated as a separate “payment” for purposes of Section 409A.  All expenses eligible for reimbursement hereunder shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. 

 
(vii)   This Agreement shall inure to the benefit of and be binding upon the Company and you, and its and your respective successors, executors, administrators, heirs and permitted assigns.  In the event of your death after the Separation Date but prior to the provision by the Company of all of the Termination Benefits described in Section 2 of this Agreement, the Company shall continue to provide such Severance Pay to your beneficiary designated in writing to the Company prior to your death (or to your estate, if you fail to make such designation).

It is Insulet’s desire and intent to make certain that you fully understand the provisions and effects of this Agreement.  To that end, the Company is providing you with seven (7) days (until April 2, 2015) to review and return a signed Agreement days to Jessica Carreiro at Insulet, 600 Technology Park Drive Suite 200, Billerica, MA 01821.  By executing this Agreement, you are acknowledging that you have been afforded sufficient time to understand the terms and effects of this Agreement and to consult with legal counsel, that your agreements and obligations hereunder are made voluntarily, knowingly and without duress, and that neither the Company nor its agents or representatives have made any representations inconsistent with the provisions of this Agreement.  
 

	
				
	 
	 
	 
	Yours very truly,

	 
	 
	 
	 

	 
	 
	 
	Insulet Corporation

	 
	 
	 
	 

	 
	 
	By:
	/s/ Brad Thomas

	 
	 
	 
	Brad Thomas

	 
	 
	 
	EVP, HR & Organization Development

	 
	 
	 
	 

	/s/ Allison Dorval
	 
	 

	Allison Dorval
	 
	 

	 
	 
	 
	 

	Dated:
	April 1, 2015
	 
	 

EXHIBIT A

I hereby reaffirm in its entirety the provisions of the Separation Agreement with Insulet Corporation dated April 1, 2015 signed by me including, without limitation, the Release of Claims contained in Section 8 of the Separation Agreement.

	
			
	/s/ Allison Dorval
	 

	Allison Dorval
	 

	 
	 
	 

	Dated:
	April 1, 2015
	 

EXHIBIT B

Insulet Corporation Amended and Restated Executive Severance Plan

EXHIBIT C

Employee Nondisclosure and Developments Agreement

And

Non-Competition and Non-Solicitation Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00243-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00243-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00243-of-00352.parquet"}]]